About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CORT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 3, 2026Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Sy…
NCT03604198 · Cushing Syndrome
relacorilant
CORT
Corcept Therapeutics
Phase 2Active, not recruiting125Dec 2026Registry ↗
Oct 16, 2026Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-…
Miricorilant
CORT
Corcept Therapeutics
Phase 1Completed14Sep 22, 2026Registry ↗
Sep 30, 2026Evaluation of Miricorilant on Liver Fat in Patients With MASLD
NCT06947304 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-…
Miricorilant
CORT
Corcept Therapeutics
Phase 1Completed9Aug 13, 2026Registry ↗
Sep 29, 2026A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metab…
NCT06108219 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-…
Miricorilant (Cohort A), Placebo (Cohort A)
CORT
Corcept Therapeutics
Phase 2Completed175Feb 13, 2026Registry ↗
Sep 25, 2026Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcin…
NCT07259317 · Adenocarcinoma, Carcinoma, Pancreatic Ductal
Relacorilant, Nab-paclitaxel
CORT
Corcept Therapeutics
Phase 2Recruiting80Sep 2027Registry ↗
Sep 25, 2026Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithel…
NCT05257408 · Ovarian Neoplasm, Fallopian Tube Neoplasms
Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2
CORT
Corcept Therapeutics
Phase 3Active, not recruiting381Mar 31, 2025Registry ↗
Sep 24, 2026Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324 · Amyotrophic Lateral Sclerosis
Dazucorilant 300 mg, Dazucorilant 150 mg
CORT
Corcept Therapeutics
Phase 2Active, not recruiting279Oct 2026Registry ↗
Aug 19, 2026Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373 · Neoplasms
Nenocorilant 200 mg, Nenocorilant 300 mg
CORT
Corcept Therapeutics
Phase 1/2Recruiting50Sep 2026Registry ↗
Jul 16, 2026Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341 · Ovarian Cancer, Fallopian Tube Cancer
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m…
CORT
Corcept Therapeutics
Phase 2Recruiting270Aug 2026Registry ↗
May 15, 2026Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metast…
NCT03437941 · Metastatic Castration-Resistant Prostate Cancer
Exicorilant, Enzalutamide
CORT
Corcept Therapeutics
Phase 1/2Terminated39Oct 13, 2021Registry ↗
Apr 13, 2026Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Health…
NCT07240116 · Healthy
Miricorilant Treatment A, Miricorilant Treatment B
CORT
Corcept Therapeutics
Phase 1Completed18Mar 3, 2026Registry ↗
Feb 17, 2026Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOM…
NCT06829537 · Resistant Hypertension, Hypercortisolism
CORT
Corcept Therapeutics
—Completed1,143Dec 8, 2025Registry ↗
Oct 7, 2025Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resis…
NCT03776812 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma
Relacorilant, Nab-paclitaxel
CORT
Corcept Therapeutics
Phase 2Completed178Mar 16, 2021Registry ↗
Sep 4, 2025A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Aden…
NCT04308590 · Hypercortisolism
Relacorilant, Placebo
CORT
Corcept Therapeutics
Phase 3Completed137Sep 19, 2024Registry ↗
Jul 16, 2025A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
NCT03697109 · Cushing Syndrome
Relacorilant, Placebo
CORT
Corcept Therapeutics
Phase 3Completed152Apr 8, 2024Registry ↗
Jul 1, 2025Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Partici…
NCT06495944 · Healthy Adults
Dazucorilant, Itraconazole
CORT
Corcept Therapeutics
Phase 1Completed21Aug 2, 2024Registry ↗
Apr 15, 2025Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT06928779 · Hepatic Impairment
Dazucorilant
CORT
Corcept Therapeutics
Phase 1Completed19Dec 9, 2024Registry ↗
Mar 30, 2025Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
NCT05553470 · Non-alcoholic Steatohepatitis (NASH)
Miricorilant
CORT
Corcept Therapeutics
Phase 1Completed19Sep 13, 2024Registry ↗
Jan 20, 2025Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatmen…
NCT05772169 · Hypercortisolism, Diabetes Mellitus, Type 2
Mifepristone 300 MG [Korlym], Placebo for mifepristone
CORT
Corcept Therapeutics
Phase 4Completed1,113Nov 19, 2024Registry ↗
Sep 19, 2024A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese…
NCT03818256 · Antipsychotic-induced Weight Gain (AIWG)
Miricorilant, Placebo
CORT
Corcept Therapeutics
Phase 2Completed71Jun 17, 2022Registry ↗
Aug 19, 2024A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in P…
NCT05320146 · Nonalcoholic Steatohepatitis (NASH)
MRI-PDFF
CORT
Corcept Therapeutics
—Completed22Jul 18, 2023Registry ↗
Aug 19, 2024A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Pres…
NCT05117489 · Nonalcoholic Steatohepatitis (NASH)
Miricorilant 150 mg, Miricorilant 100 mg
CORT
Corcept Therapeutics
Phase 1Completed70Jan 29, 2024Registry ↗
Jun 13, 2024A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patien…
NCT04524403 · Antipsychotic-induced Weight Gain (AIWG)
Miricorlilant, Miricorlilant
CORT
Corcept Therapeutics
Phase 2Completed150Jul 29, 2022Registry ↗
Feb 23, 2024Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma…
NCT04373265 · Adrenocortical Carcinoma
Relacorilant, Pembrolizumab
CORT
Corcept Therapeutics
Phase 1Completed15Oct 17, 2023Registry ↗
Nov 18, 2023Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Duc…
NCT04329949 · Metastatic Pancreatic Ductal Adenocarcinoma
Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
CORT
Corcept Therapeutics
Phase 3Terminated43Aug 23, 2021Registry ↗
Oct 23, 2023A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Health…
NCT06094790 · Healthy
CORT125134 150 mg, CORT125134 250 mg
CORT
Corcept Therapeutics
Phase 1Completed32Nov 15, 2017Registry ↗
Oct 23, 2023A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subje…
NCT06094738 · Healthy
Relacorilant under fasted conditions, Relacorilant after a…
CORT
Corcept Therapeutics
Phase 1Completed30Nov 16, 2020Registry ↗
Oct 23, 2023A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
NCT06094725 · Hepatic Impairment
Relacorilant
CORT
Corcept Therapeutics
Phase 1Completed30Dec 14, 2020Registry ↗
Oct 23, 2023A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subj…
NCT06094712 · Healthy
CORT125134
CORT
Corcept Therapeutics
Phase 1Completed8Apr 27, 2016Registry ↗
Jun 1, 2023Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
NCT02663609 · Cushing's Syndrome
No intervention
CORT
Corcept Therapeutics
—Completed24Dec 1, 2017Registry ↗
Mar 22, 2023Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Mirico…
NCT05712265 · Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepa…
Miricorilant, Fluvoxamine
CORT
Corcept Therapeutics
Phase 1Completed26Feb 23, 2023Registry ↗
Mar 22, 2023Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants
NCT05003713 · Healthy
CORT125236, Placebo matching CORT125236
CORT
Corcept Therapeutics
Phase 1Completed82Feb 3, 2023Registry ↗
Feb 9, 2023Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran…
NCT05347979 · Cushing Syndrome, Neoplasms
Dabigatran Etexilate, Relacorilant
CORT
Corcept Therapeutics
Phase 1Completed30Jul 19, 2022Registry ↗
Dec 6, 2022Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With…
NCT02762981 · Solid Tumors
Relacorilant with nab-paclitaxel
CORT
Corcept Therapeutics
Phase 1/2Completed85May 12, 2020Registry ↗
Aug 31, 2022Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Pr…
NCT03823703 · Nonalcoholic Steatohepatitis (NASH)
Miricorilant, Placebo
CORT
Corcept Therapeutics
Phase 2Terminated12Apr 5, 2021Registry ↗
Feb 9, 2022Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
NCT04672512 · Healthy
CORT125329 lipid capsule formulation, Placebo
CORT
Corcept Therapeutics
Phase 1Completed115Jan 17, 2022Registry ↗
Feb 8, 2022A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male…
NCT00698022 · Healthy
Risperidone, Mifepristone
CORT
Corcept Therapeutics
Phase 1Completed76Feb 2009Registry ↗
Feb 1, 2022Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
NCT04249323 · Healthy Adults
CORT113176 Lipid Capsule Formulation, Placebo matching CORT…
CORT
Corcept Therapeutics
Phase 1Completed110Oct 15, 2020Registry ↗
Nov 24, 2021Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Health…
NCT04990310 · Healthy
[14C]-CORT113176
CORT
Corcept Therapeutics
Phase 1Completed6Sep 20, 2021Registry ↗
Oct 11, 2021Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants
NCT04994743 · Healthy Adults
CORT113176, Placebo matching CORT113176
CORT
Corcept Therapeutics
Phase 1Completed16Sep 30, 2021Registry ↗
Sep 14, 2021T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
NCT04795479 · Healthy
Relacorilant, Placebo to relacorilant
CORT
Corcept Therapeutics
Phase 1Completed36May 17, 2021Registry ↗
Dec 17, 2020Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Particip…
NCT04672499 · Healthy
Miricorilant 300 mg tablets, Miricorilant 150 mg tablets
CORT
Corcept Therapeutics
Phase 1Completed36Sep 7, 2020Registry ↗
Apr 28, 2020The Effect of CORT118335 on Olanzapine-Induced Weight Gain
NCT03877562 · Antipsychotic-induced Weight Gain
Olanzapine, CORT118335
CORT
Corcept Therapeutics
Phase 1Completed96Mar 13, 2020Registry ↗
Mar 24, 2020Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and I…
NCT03512548 · Healthy
Relacorilant 350mg, Itraconazole
CORT
Corcept Therapeutics
Phase 1Completed52Jul 29, 2019Registry ↗
Oct 15, 2019Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
NCT02804750 · Cushing's Syndrome
CORT125134
CORT
Corcept Therapeutics
Phase 2Completed35Sep 2018Registry ↗
Aug 9, 2019CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT03508635 · Healthy
CORT125134, Matching Placebo of CORT125134
CORT
Corcept Therapeutics
Phase 1Completed130Dec 2015Registry ↗
Aug 9, 2019A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
NCT03067376 · Healthy
[14C]-CORT125134
CORT
Corcept Therapeutics
Phase 1Completed9Sep 2016Registry ↗
Jul 30, 2019Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
NCT03379363 · Hypercortisolism, Cushing Syndrome
CORT
Corcept Therapeutics
—Terminated2Feb 12, 2018Registry ↗
Jun 11, 2019Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
NCT03878264 · Healthy
CORT118335 Oral, 14C-CORT118335 intravenous
CORT
Corcept Therapeutics
Phase 1Completed12Mar 24, 2019Registry ↗
May 24, 2019First-in-human Study in Healthy Subjects
NCT03315338 · Healthy
CORT118335, 25 mg, Prednisone Oral Tablet
CORT
Corcept Therapeutics
Phase 1Completed143Feb 22, 2019Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances